"Melanoma, Experimental" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Experimentally induced tumor that produces MELANIN in animals to provide a model for studying human MELANOMA.
| Descriptor ID |
D008546
|
| MeSH Number(s) |
C04.557.465.625.650.510.525 C04.557.580.625.650.510.525 C04.557.665.510.525 C04.619.600 E05.598.500.496.937
|
| Concept/Terms |
Melanoma, Experimental- Melanoma, Experimental
- Melanomas, Experimental
- Experimental Melanoma
- Experimental Melanomas
Melanoma, B16- Melanoma, B16
- B16 Melanomas
- Melanomas, B16
- B16 Melanoma
|
Below are MeSH descriptors whose meaning is more general than "Melanoma, Experimental".
- Diseases [C]
- Neoplasms [C04]
- Neoplasms by Histologic Type [C04.557]
- Neoplasms, Germ Cell and Embryonal [C04.557.465]
- Neuroectodermal Tumors [C04.557.465.625]
- Neuroendocrine Tumors [C04.557.465.625.650]
- Melanoma [C04.557.465.625.650.510]
- Melanoma, Experimental [C04.557.465.625.650.510.525]
- Neoplasms, Nerve Tissue [C04.557.580]
- Neuroectodermal Tumors [C04.557.580.625]
- Neuroendocrine Tumors [C04.557.580.625.650]
- Melanoma [C04.557.580.625.650.510]
- Melanoma, Experimental [C04.557.580.625.650.510.525]
- Nevi and Melanomas [C04.557.665]
- Melanoma [C04.557.665.510]
- Melanoma, Experimental [C04.557.665.510.525]
- Neoplasms, Experimental [C04.619]
- Melanoma, Experimental [C04.619.600]
- Analytical, Diagnostic and Therapeutic Techniques and Equipment [E]
- Investigative Techniques [E05]
- Models, Animal [E05.598]
- Disease Models, Animal [E05.598.500]
- Neoplasms, Experimental [E05.598.500.496]
- Melanoma, Experimental [E05.598.500.496.937]
Below are MeSH descriptors whose meaning is more specific than "Melanoma, Experimental".
This graph shows the total number of publications written about "Melanoma, Experimental" by people in this website by year, and whether "Melanoma, Experimental" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 |
| 1996 | 1 | 0 | 1 |
| 1998 | 1 | 0 | 1 |
| 1999 | 0 | 2 | 2 |
| 2001 | 1 | 0 | 1 |
| 2004 | 0 | 1 | 1 |
| 2006 | 0 | 2 | 2 |
| 2007 | 2 | 1 | 3 |
| 2008 | 1 | 1 | 2 |
| 2009 | 2 | 0 | 2 |
| 2010 | 1 | 2 | 3 |
| 2011 | 1 | 0 | 1 |
| 2012 | 0 | 3 | 3 |
| 2013 | 1 | 0 | 1 |
| 2014 | 2 | 1 | 3 |
| 2015 | 2 | 1 | 3 |
| 2016 | 1 | 1 | 2 |
| 2017 | 4 | 0 | 4 |
| 2019 | 4 | 2 | 6 |
| 2020 | 2 | 0 | 2 |
| 2021 | 2 | 2 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Melanoma, Experimental" by people in Profiles.
-
Combinatorial immunotherapy induces tumor-infiltrating CD8+ T cells with distinct functional, migratory, and stem-like properties. J Immunother Cancer. 2021 12; 9(12).
-
Type 2 dendritic cells mediate control of cytotoxic T cell resistant tumors. JCI Insight. 2021 09 08; 6(17).
-
MnO2-Based Nanomotors with Active Fenton-like Mn2+ Delivery for Enhanced Chemodynamic Therapy. ACS Appl Mater Interfaces. 2021 Aug 18; 13(32):38050-38060.
-
Extracts of select endemic plants from the Republic of Mauritius exhibiting anti-cancer and immunomodulatory properties. Sci Rep. 2021 02 19; 11(1):4272.
-
The Unfolded Protein Response Mediator PERK Governs Myeloid Cell-Driven Immunosuppression in Tumors through Inhibition of STING Signaling. Immunity. 2020 04 14; 52(4):668-682.e7.
-
ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy. J Immunother Cancer. 2020 04; 8(1).
-
Endoplasmic Reticulum Protein Disulfide Isomerase Shapes T Cell Efficacy for Adoptive Cellular Therapy of Tumors. Cells. 2019 11 26; 8(12).
-
SLC36A1-mTORC1 signaling drives acquired resistance to CDK4/6 inhibitors. Sci Adv. 2019 09; 5(9):eaax6352.
-
Pro-Survival Lipid Sphingosine-1-Phosphate Metabolically Programs T Cells to Limit Anti-tumor Activity. Cell Rep. 2019 08 13; 28(7):1879-1893.e7.
-
Anticancer activity of emodin is associated with downregulation of CD155. Int Immunopharmacol. 2019 Oct; 75:105763.